We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients. (A7881013)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00808288
Recruitment Status : Completed
First Posted : December 15, 2008
Last Update Posted : February 6, 2019
Information provided by (Responsible Party):

Brief Summary:
To assess the effects and safety of PF-00610355 on patients with chronic obstructive lung disease (COPD)

Condition or disease Intervention/treatment Phase
Pulmonary Disease, Chronic Obstructive Lung Diseases Lung Diseases, Obstructive Drug: PF-00610355 Drug: PF - 00610355 Drug: PF- 00610355 Drug: Placebo Drug: Salmeterol Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 405 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2b, Parallel Group, Placebo And Active Comparator Controlled Study To Investigate The Safety, Toleration And Efficacy Of 6-Week Once Daily Administration Of Inhaled PF-00610355 Dry Powder In Patients With Moderate Chronic Obstructive Pulmonary Disease.
Study Start Date : March 2010
Actual Primary Completion Date : December 2010
Actual Study Completion Date : December 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: COPD Lung Diseases

Arm Intervention/treatment
Experimental: PF-00610355 Drug: PF-00610355
oral, inhaled, dry powder, 600ug, OD

Experimental: PF- 00610355 Drug: PF - 00610355
oral, inhaled, dry powder, 300ug, OD

Experimental: PF - 00610355 Drug: PF- 00610355
oral, inhaled, dry powder, 100ug, OD

Placebo Comparator: Placebo Drug: Placebo
oral, inhaled, dry powder, placebo, OD

Active Comparator: Salmeterol Drug: Salmeterol
salmeterol, 50ug, BID

Primary Outcome Measures :
  1. Change from baseline in trough FEV1 [ Time Frame: 6 week ]

Secondary Outcome Measures :
  1. Maximal and mean changes from baseline in heart rate, QTc and plasma potassium [ Time Frame: each visit ]
  2. Change from baseline in peak FEV1 [ Time Frame: 0-6 hours /6 weeks ]
  3. Change from baseline in trough and peak FEV6, FVC and IC [ Time Frame: 6 weeks ]
  4. Change from baseline in trough FEV1, FEV6, forced vital capacity (FVC) and inspiratory capacity (IC) [ Time Frame: 2 and 4 weeks ]
  5. Change from baseline in Respiratory Questionnaire Self-Administered Standardised (CRQ-SAS) [ Time Frame: 2,4,6 weeks ]
  6. Change from baseline of COPD symptoms and rescue bronchodilator use (per daily diary). [ Time Frame: weekly ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Post-bronchodilator FEV1/FVC ratio <0.7 and a post-bronchodilator FEV1 of 50-80%.
  • Diagnosis of moderate COPD for a minimum of 6 months.
  • Stable disease for at least 1 month prior to screening

Exclusion Criteria:

  • More than 2 exacerbations of COPD requiring treatment with oral steroids in the preceding year or hospitalisation for the treatment of COPD within 3 months of screening or more than twice during the preceding year.
  • History of a lower respiratory tract infection or significant disease instability during the month preceding screening or during the time between screening and randomisation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00808288

Show Show 75 study locations
Sponsors and Collaborators
Layout table for investigator information
Study Director: Pfizer CT.gov Call Center Pfizer
Additional Information:
Layout table for additonal information
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT00808288    
Other Study ID Numbers: A7881013
First Posted: December 15, 2008    Key Record Dates
Last Update Posted: February 6, 2019
Last Verified: February 2019
Keywords provided by Pfizer:
COPD Respiratory Long acting beta agonist
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases
Salmeterol Xinafoate
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action